Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutant IDH1 is required for IDH1 mutated tumor cell growth.

Oncotarget - 1 Aug 2012

Jin Genglin, Pirozzi Christopher J, Chen Lee H, Lopez Giselle Y, Duncan Christopher G, Feng Jie, Spasojevic Ivan, Bigner Darell D, He Yiping, Yan Hai

Abstract excerpt

Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protein is required for maintaining IDH1 mutated tumor cell growth remains unknown. Here, using a genetically engineered inducible system, we report that selective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fibrosarcoma

Share to IDH1 gene

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to RNA Interference

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 22885298
DOI: 10.18632/oncotarget.577
PMCID: PMC3478455

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutant IDH1 is required for IDH1 mutated tumor cell growth.PMID 22885298Read ↗

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.Semantic proximity Read ↗

Selective inhibition of mutant IDH1 by DS-1001b ameliorates aberrant histone modifications and impairs tumor activity in chondrosarcomaSemantic proximity Read ↗

The implications of IDH mutations for cancer development and therapy.Semantic proximity Read ↗

Mutant IDH1 Promotes Glioma Formation In VivoSemantic proximity Read ↗

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Semantic proximity Read ↗

Functional requirement of a wild-type allele for mutant IDH1 to suppress anchorage-independent growth through redox homeostasis.Semantic proximity Read ↗

Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.Semantic proximity Read ↗

New developments in the pathogenesis and therapeutic targeting of the IDH1 mutation in glioma.Semantic proximity Read ↗

HDAC1 and HDAC6 are essential for driving growth in IDH1 mutant glioma.Semantic proximity Read ↗

Induction of sarcomas by mutant IDH2.Semantic proximity Read ↗

Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.